Promising Developments in CAR-T Therapy with NT-I7
NeoImmuneTech, Inc. has achieved significant advancements in enhancing CAR-T cell therapies, which are innovative treatments designed to combat cancer. Recent interim results from the Phase 1b clinical trial demonstrate the potential benefits of combining NT-I7 (efineptakin alfa) with CAR-T therapy, highlighting its promise for improving patient care.
Challenges Faced by CAR-T Cell Therapy
Though CAR-T therapies mark a major breakthrough in cancer treatment, they often encounter issues with sufficient cell expansion and long-term persistence. These challenges can hinder their effectiveness during treatment. To tackle these issues, NeoImmuneTech's latest clinical findings indicate that administering NT-I7 after CAR-T cell infusion is both safe and well tolerated.
Details of Clinical Trial NIT-112
The NIT-112 clinical trial targets patients diagnosed with Large B-cell Lymphoma (LBCL) who have previously undergone CAR-T therapies, including Kymriah, Yescarta, or Breyanzi. Participants received NT-I7 treatment 21 days following their CAR-T infusion. The trial aims to assess not only safety and tolerability but also to determine the recommended Phase 2 dose (RP2D) and the potential of NT-I7 to enhance CAR-T cell expansion and durability.
Consistent Safety Profile Observed
Initial results from doses 4 and 5 of NT-I7 (360 and 480 µg/kg) reveal encouraging outcomes. Notably, there were no incidents of Cytokine Release Syndrome (CRS) or Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), which are serious side effects commonly associated with CAR-T therapies. The mild side effects that were observed were manageable and affected most participants to a lesser extent.
Enhancement of CAR-T Cells
The introduction of NT-I7 led to a significant increase in CAR-T cell numbers, demonstrated prolonged cell persistence, and raised the proportion of T cells displaying a stem-cell memory phenotype. This resulted in an overall response rate (ORR) of 81.1% among participants, a stark contrast to the 52% ORR seen in previous studies involving Kymriah.
Insights from the CEO
Dr. Luke Oh, President and CEO of NeoImmuneTech, expressed his excitement regarding the preliminary findings of the NIT-112 study. He emphasized the importance of NT-I7 in amplifying CAR-T cells and its potential to positively influence patient outcomes. NeoImmuneTech is looking into technology transfer opportunities for the combination of NT-I7 with CAR-T therapies, paving the way for even more effective treatments in the future.
Understanding NT-I7 (efineptakin alfa)
NT-I7 is a long-acting human IL-7 that plays a vital role in T cell development and in maintaining immune responses against chronic antigens such as cancer. Its favorable pharmacokinetics and safety profile make it an ideal candidate for combination therapies. Ongoing research is exploring NT-I7’s potential across various cancer types and its application as a vaccine adjuvant.
About NeoImmuneTech, Inc.
NeoImmuneTech, Inc. is committed to advancing T cell-focused immunotherapies and enhancing the battle against infectious diseases. The company boasts a strong leadership team with extensive expertise in the field. As NeoImmuneTech continues to expand, it remains dedicated to collaborating with industry and academic leaders to explore the therapeutic possibilities offered by NT-I7.
Frequently Asked Questions
What is the NIT-112 clinical trial about?
The NIT-112 trial investigates the safety and effectiveness of NT-I7 in conjunction with CAR-T cell therapies for patients with Large B-cell Lymphoma.
What are the main results of the interim findings?
Interim results show a stable safety profile for NT-I7, with an ORR of 81.1%, highlighting its potential to improve patient outcomes.
Who is leading NeoImmuneTech?
Dr. Luke Oh serves as the President and CEO, guiding the company’s innovative approach to immunotherapy.
What other clinical applications is NT-I7 being studied for?
NT-I7 is being evaluated not only in hematological malignancies but also in solid tumors and as a vaccine adjuvant.
How does NT-I7 enhance CAR-T therapies?
NT-I7 improves CAR-T cell persistence and expansion, thereby potentially increasing the overall effectiveness of the treatment.
